Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to ...

Timing Trades in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA can be Risky if you Don't Have ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

Teva Pharmaceutical Industries Limited ( NYSE: TEVA) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief ...

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) and increased ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Teva (TEVA) announced that it has entered into a strategic collaboration with Klinge Biopharma and Formycon for the semi-exclusive ...

Samsung Bioepis collaborates with Teva to launch Epysylli in U.S. market Samsung Bioepis and Teva join forces to introduce a ...

Technical analysis for Teva Pharmaceutical Industries Limited American Depositary Shares TEVA including support levels ...